Chaosu Hu

10PUBLICATIONS
59CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 11, 2026
Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

|Apr 07, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.

Shuang Huang, Feng Liu, Song Qu

|Jun 18, 2024
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.

Xiaozhong Chen, Wei Wang, Qingfeng Zou

|Apr 25, 2024
PICK1 inhibits the malignancy of nasopharyngeal carcinoma and serves as a novel prognostic marker.

Xiaomin Ou, Yingzi Zhang, Yiqing Xu

|Apr 09, 2024
Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy: A propensity score-matched analysis.

Yujiao Li, Xiyin Guan, Xing Xing

|Feb 13, 2024
Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance.

Yang Liu, Wenbin Yan, Chaosu Hu

Pageof 2

Frequent Collaborators

3 joint publications

Tingting Xu

3 joint publications

Xiaomin Ou

2 joint publications

Junlin Yi

2 joint publications

Yu Wang